DK0584266T3 - Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf - Google Patents

Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf

Info

Publication number
DK0584266T3
DK0584266T3 DK92913153T DK92913153T DK0584266T3 DK 0584266 T3 DK0584266 T3 DK 0584266T3 DK 92913153 T DK92913153 T DK 92913153T DK 92913153 T DK92913153 T DK 92913153T DK 0584266 T3 DK0584266 T3 DK 0584266T3
Authority
DK
Denmark
Prior art keywords
cea
methods
recombinant virus
virus expressing
embryonic antigen
Prior art date
Application number
DK92913153T
Other languages
English (en)
Inventor
Jeffrey Schlom
Judith Kantor
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK0584266T3 publication Critical patent/DK0584266T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK92913153T 1991-05-06 1992-05-06 Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf DK0584266T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69502491A 1991-05-06 1991-05-06
US87964992A 1992-05-06 1992-05-06
PCT/US1992/003843 WO1992019266A1 (en) 1991-05-06 1992-05-06 Recombinant virus expressing carcinoembryonic antigen and methods of use thereof

Publications (1)

Publication Number Publication Date
DK0584266T3 true DK0584266T3 (da) 2003-12-29

Family

ID=27105497

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92913153T DK0584266T3 (da) 1991-05-06 1992-05-06 Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf

Country Status (10)

Country Link
US (1) US5698530A (da)
EP (1) EP0584266B1 (da)
JP (1) JP3399943B2 (da)
AT (1) ATE248924T1 (da)
AU (1) AU674492B2 (da)
CA (1) CA2102623C (da)
DE (1) DE69233186T2 (da)
DK (1) DK0584266T3 (da)
ES (1) ES2206446T3 (da)
WO (1) WO1992019266A1 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
AT399656B (de) * 1993-03-19 1995-06-26 Boehringer Ingelheim Int Verfahren zur herstellung von krebsvakzinen
US6093700A (en) * 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
ES2154738T3 (es) 1994-10-03 2001-04-16 Us Gov Health & Human Serv Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
CA2213439A1 (en) * 1995-02-24 1996-08-29 The Trustees Of The University Of Pennsylvania Methods and compositions for administering gene therapy vectors
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US5480640A (en) * 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
EP0954593A1 (en) * 1996-07-25 1999-11-10 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
WO1998029556A1 (en) * 1996-12-31 1998-07-09 The Wistar Institute Recombinant adenoviral vector expressing antigens associated with colorectal tumors
DE19716892C1 (de) * 1997-04-22 1998-09-03 Gsf Forschungszentrum Umwelt Expression von Immunglobulin-Zytokin-Fusionsproteinen in malignen B-Zellen
US6120806A (en) * 1997-06-25 2000-09-19 Whitmire; David R. Oral formulations for controlled release of alcohol deterrents
KR20010022863A (ko) * 1997-08-13 2001-03-26 피터 브이. 오`네일 유전자 벡터의 국소 적용에 의한 백신접종
EP1017810B1 (en) * 1997-10-10 2004-05-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Agonist and antagonist peptides of carcinoembryonic antigen (cea)
US6756038B1 (en) 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
US6506385B1 (en) 1998-04-17 2003-01-14 Embrex, Inc. Live vaccines and methods of treatment therewith
US7148035B1 (en) 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
US6896881B1 (en) * 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
WO2001085932A2 (en) 2000-05-10 2001-11-15 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
WO2003050268A2 (en) * 2001-12-12 2003-06-19 Aventis Pasteur Limited Enhancement of the immune response using cd36-binding domain
WO2003059379A2 (en) * 2002-01-17 2003-07-24 Pharmexa A/S Immunogenic carcinoembryonic antigen (cea)
US6949629B2 (en) * 2002-03-13 2005-09-27 Aspenbio, Inc. Methods for purifying selected CEA family member proteins
PT1496939E (pt) * 2002-04-09 2007-11-22 Sanofi Pasteur Ltd ''ácido nucleico de cea modificado e vectores de expressão''
WO2005035773A2 (en) * 2003-10-08 2005-04-21 Sanofi Pasteur, Inc. Modified cea /b7 vector
AU2003278036B2 (en) * 2002-10-22 2009-12-10 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
JP2006518202A (ja) * 2003-02-13 2006-08-10 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー アカゲザル癌胎児性抗原、前記抗原をコードするヌクレオチド、及びその使用
EP1658370A1 (en) * 2003-08-22 2006-05-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof
WO2005077977A2 (en) * 2004-02-11 2005-08-25 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Carcinoembryonic antigen fusions proteins and uses thereof
CN105039266A (zh) 2008-03-14 2015-11-11 赛诺菲巴斯德生物制剂有限责任公司 复制缺陷型黄病毒疫苗和疫苗载体
BR112013020875A2 (pt) 2011-02-15 2019-09-24 Immune Design Corp método para indução de uma resposta imune específica para um imunógeno em um indivíduo.
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
RS57420B1 (sr) 2012-05-16 2018-09-28 Immune Design Corp Vakcine za hsv-2
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
EP3104878B1 (en) 2014-02-14 2019-05-22 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
WO2016011083A1 (en) 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
WO2017120204A2 (en) 2016-01-05 2017-07-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
KR20230051602A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
NZ746934A (en) 2016-04-15 2023-11-24 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CN110809581A (zh) 2017-03-16 2020-02-18 高山免疫科学股份有限公司 Pd-l2变体免疫调节蛋白及其用途
RS64870B1 (sr) 2017-03-16 2023-12-29 Alpine Immune Sciences Inc Imunomodulatorni proteini varijante pd-l1 i njihove upotrebe
SG11201907769XA (en) 2017-03-16 2019-09-27 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
JP7247097B2 (ja) * 2017-03-17 2023-03-28 バクシム アクチェンゲゼルシャフト がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン
SG11201908280SA (en) 2017-03-30 2019-10-30 Univ Queensland "chimeric molecules and uses thereof"
WO2019040994A1 (en) 2017-09-01 2019-03-07 The Australian National University IMMUNOREGULATOR MOLECULES AND USES THEREOF
EP4219540A3 (en) 2017-10-10 2023-12-06 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
TW201925223A (zh) 2017-10-18 2019-07-01 美商艾爾潘免疫科學有限公司 變異型icos 配位體免疫調節蛋白及相關組合物及方法
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
AU2019345151A1 (en) 2018-09-19 2021-04-29 Alpine Immune Sciences, Inc. Methods and uses of variant CD80 fusion proteins and related constructs
WO2020113141A2 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
CN114302736A (zh) 2019-04-17 2022-04-08 高山免疫科学股份有限公司 变体icos配体(icosl)融合蛋白的方法和用途
MX2022013998A (es) 2020-05-08 2023-02-16 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff con y sin una proteina inhibidora de celulas t y metodos de uso de las mismas.
US20240279310A1 (en) 2021-05-07 2024-08-22 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
DE3787864T2 (de) * 1986-08-13 1994-02-10 Miles Inc Karzinoembryonisches Antigen kodierende cDNS.
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens

Also Published As

Publication number Publication date
CA2102623A1 (en) 1992-11-07
EP0584266A4 (en) 1995-04-05
EP0584266B1 (en) 2003-09-03
DE69233186T2 (de) 2004-06-03
AU2006092A (en) 1992-12-21
ATE248924T1 (de) 2003-09-15
JP3399943B2 (ja) 2003-04-28
ES2206446T3 (es) 2004-05-16
EP0584266A1 (en) 1994-03-02
CA2102623C (en) 2003-04-22
US5698530A (en) 1997-12-16
DE69233186D1 (de) 2003-10-09
JPH06508025A (ja) 1994-09-14
AU674492B2 (en) 1997-01-02
WO1992019266A1 (en) 1992-11-12

Similar Documents

Publication Publication Date Title
DK0584266T3 (da) Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
NZ512247A (en) Compositions and methods for therapy and diagnosis of ovarian cancer
HK1044798A1 (en) Her-2/neu fusion proteins.
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
WO1998037095A3 (en) Recombinant pox virus for immunization against muc1 tumor-associated antigen
DE69333471D1 (de) Erzielbare vektorenpartikel
WO1989001973A3 (en) Recombinant pox virus for immunization against tumor-associated antigens
CA2033640A1 (en) Vaccines against cancer and infectious diseases
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
ATE328068T1 (de) Papillomavirus vakzine
ATE215125T1 (de) ßHEAT SHOCKß-PROTEINE UND BEHANDLUNG VON TUMOREN
ATE328091T1 (de) Oligoepitop-peptid des prostata-spezifischen antigens
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
DK0843731T3 (da) Adenovirusvektorer til genterapi
HUP9902150A2 (hu) Rekombináns adenovírus vektorok humán tumor génterápiára
NO932101L (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
NO930798L (no) Fremgangsmaate og middel mot tumorer
NO884324D0 (no) Fremgangsmaate til fremstilling av reninhemmende peptider og deres anvendelse.
EP0684831A4 (en) ALLOGENIC VACCINE AND METHOD FOR SYNTHESIZING THE SAME.
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt